Display options
Cite
Iacovelli R, Modica D, Palazzo A, et al. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015;9(3):E172-7doi: 10.5489/cuaj.2373.
Iacovelli, R., Modica, D., Palazzo, A., Trenta, P., Piesco, G., & Cortesi, E. (2015). Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 9(3), E172-7. https://doi.org/10.5489/cuaj.2373
Iacovelli, Roberto, et al. "Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 9,3 (2015): E172-7. doi: https://doi.org/10.5489/cuaj.2373
Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015 Mar-Apr;9(3):E172-7. doi: 10.5489/cuaj.2373. PMID: 26085875; PMCID: PMC4455635.
Copy Download .nbib Format: NLM
Share it on

Can Urol Assoc J. 2015 Mar-Apr;9(3):E172-7. doi: 10.5489/cuaj.2373.

Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Roberto Iacovelli, Daniela Modica, Antonella Palazzo, Patrizia Trenta, Gabriele Piesco, Enrico Cortesi

Affiliations

  1. Sapienza University of Rome; Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Rome, Italy.

PMID: 26085875 PMCID: PMC4455635 DOI: 10.5489/cuaj.2373

Abstract

INTRODUCTION: We describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995.

METHODS: A systematic search was performed to identify all articles describing patients with medullary renal cancer until February 2013. Survivals were estimated using Kaplan-Meier method with 95% confidence intervals and compared across the groups using the log-rank test. The following factors were evaluated using the Cox proportional hazards model: association of extension of disease at diagnosis, response to therapy, and surgical treatment of primary tumour with overall.

RESULTS: A total 47 articles were selected; these described 165 patients with RMC plus 1 from our centre. The median age was 21 years and 98% of cases had the sickle cell trait. The mean size of the primary tumours was 6.0 cm, with an involvement of loco-regional lymph nodes in 71% of cases. The overall survival at diagnosis was 4.0 months in metastatic patients and 17.0 months in non-metastatic patients. Patients who received platinum-paclitaxel-gemcitabine had longer control of the disease when compared to topoisomerase inhibitors or targeted therapies. The multivariate analysis confirmed that the advanced stage at diagnosis increased the risk of death of about threefold.

CONCLUSION: RMC is a tumour with poorer prognosis; based on these results, platinum-based chemotherapy is the preferred systemic treatment. Even if radical nephrectomy as an up-front strategy did not report a survival benefit, it may be considered to palliate local symptoms and to perform a correct diagnosis.

References

  1. Am J Surg Pathol. 1995 Jan;19(1):1-11 - PubMed
  2. Cancer. 2004 Mar 1;100(5):976-85 - PubMed
  3. J Urol. 2009 Aug;182(2):735-40 - PubMed
  4. Kidney Int. 2000 Jan;57(1):1-8 - PubMed
  5. Med Pediatr Oncol. 1999 Dec;33(6):551-7 - PubMed
  6. Eur J Radiol. 2000 Jul;35(1):1-7 - PubMed
  7. Radiology. 1995 Apr;195(1):83-5 - PubMed
  8. Radiographics. 2005 Mar-Apr;25(2):369-80 - PubMed
  9. Urology. 2002 Dec;60(6):1083-9 - PubMed
  10. Am J Hematol. 2000 Apr;63(4):205-11 - PubMed

Publication Types